GlobeNewswire Inc | Sep 9, 2021 08:00AM EDT

September 09, 2021

WILMETTE, Ill., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced that Chandler D. Robinson, MD, Chief Executive Officer,isscheduledto present a Company overview at thefollowing investor conferencesin September:

H.C.Wainwright 23rd Annual Global Investment ConferenceThe Companys presentation will be webcast on Monday, September 13, 2021at 7:00 a.m. ET

Cantor Virtual Global HealthcareConference 2021The Companys presentation will be webcast on Thursday, September 30, 2021at11:20 a.m. ET, Track 7

AboutMonoparTherapeuticsInc.

MonoparTherapeutics is a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients.Monopar'spipeline consists ofValidivefor the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients; camsirubicinfor the treatmentof advanced soft tissue sarcoma; a late-stage preclinical antibody, MNPR-101, for advanced cancers and severe COVID-19; and an early-stage camsirubicin analog, MNPR-202, for various cancers. For more information, visit:www.monopartx.com.

CONTACT:

Monopar Therapeutics Inc.Investor RelationsKim R. TsuchimotoChief Financial Officerkimtsu@monopartx.com

Follow Monopar on social media for updates:

Twitter: @MonoparTx LinkedIn: Monopar Therapeutics